Aspiro Therapeutics CEO to Speak at Global RESCON Summit 2026
Tucson, Arizona | September 3, 2026 – Aspiro Therapeutics will participate in the Global RESCON Summit 2026, where Chief Executive Officer and Co-Founder James Lovgren will serve as a featured speaker. Taking place November 10–11, 2026, in Porto, Portugal, the conference brings together leaders from industry, academia, regulatory agencies, and investment to discuss advances in […]
Aspiro Therapeutics to Participate in RESI San Diego 2026
Tucson, Arizona | June 2, 2026 – Aspiro Therapeutics will participate in RESI San Diego 2026, one of the leading partnering conferences for early-stage life science companies, bringing together biotechnology innovators, investors, strategic partners, and industry leaders to accelerate the development of innovative healthcare technologies. During the conference, Chief Executive Officer and Co-Founder James Lovgren […]
Aspiro Therapeutics to Present at ATS Respiratory Innovation Summit 2026
Tucson, Arizona / April 14, 2026 — Aspiro Therapeutics, a preclinical-stage biopharmaceutical company pioneering the development of groundbreaking, disease-modifying therapies for obstructive lung diseases, today announced that it will present new data at the American Thoracic Society Respiratory Innovation Summit (RIS), taking place May 15 to 16, 2026 in Orlando, Florida. The poster highlights a […]
Aspiro Therapeutics to Attend JPM Week 2026
Tucson, Arizona / January 5, 2026 — Aspiro Therapeutics will be attending JPM Week 2026 in San Francisco, where the team will be meeting with investors, industry leaders, and potential partners focused on innovation in respiratory medicine. During the week, Aspiro will engage in discussions around the evolving treatment landscape for obstructive lung diseases, including […]
Aspiro Co-founders Leading $3.8M NIH Study on Early Detection of COPD
Tucson, Arizona / August 18, 2025 —Aspiro Therapeutics is proud to share that two of our co-founders, Dr. Stefano Guerra and Dr. Julie Ledford, are contributing to a newly awarded $3.8 million grant from the National Institute of Allergy and Infectious Diseases (NIAID) focused on CC16 and its role in early chronic obstructive pulmonary disease […]
Aspiro Therapeutics Establishes Advisory Board to Support Development of Lead Therapy
Tucson, Arizona / June 11, 2025 — Aspiro Therapeutics, a preclinical-stage biopharmaceutical company pioneering the development of groundbreaking, disease-modifying therapies for obstructive lung diseases, today announced the strategic addition of two new advisors: Matt Britz and Dr. Anne Dixon. Their combined leadership in respiratory science, clinical development, and biotech company building will significantly support Aspiro’s […]
Aspiro Therapeutics Selected to Present at 2025 BIO Startup Stadium
Tucson, Arizona / May 28, 2025 — Aspiro Therapeutics, a preclinical-stage biopharmaceutical company pioneering the development of groundbreaking, disease-modifying therapies for obstructive lung diseases, today announced its selection to present at the BIO 2025 Startup Stadium, part of the BIO International Convention taking place June 17 to 20 in Boston, Massachusetts. Aspiro will present its […]
Aspiro Therapeutics Selected to Present at 2025 Respiratory Innovation Summit
Tucson, Arizona / April 17, 2025 — Aspiro Therapeutics, a biopharmaceutical company dedicated to pioneering the development of groundbreaking treatments for obstructive lung diseases, announced today that it has been selected as a Showcase Company at the 2025 Respiratory Innovation Summit (RIS), hosted by the American Thoracic Society (ATS). Aspiro’s CEO and Co-Founder, James Lovgren, […]
Integration of biobank-scale genetics and plasma proteomics reveals evidence for causal processes in asthma risk and heterogeneity
In brief Plasma proteomics may capture key insights into disease mechanisms and reveal informative biomarkers. Donoghue et al. apply a causal inference framework to genetic and plasma proteomic data from the UK Biobank and demonstrate that genetically predicted protein levels are effective instruments for identifying putatively causal factors underlying both disease risk and heterogeneity. […]
Aspiro Therapeutics Named Finalist in Flinn Foundation Bioscience Entrepreneurship Program
Tucson, AZ / March 7, 2025 – Aspiro Therapeutics, a biotechnology company developing next-generation treatments for obstructive lung diseases, has been selected as a finalist in the Flinn Foundation Bioscience Entrepreneurship Program. The program recognizes Arizona-based bioscience startups with high-impact innovations poised to improve human health. Aspiro is focused on advancing disease-modifying therapies for respiratory […]